Table 1.
Characteristics of the included studies.
| Author (original trial) | Inclusion criteria | No. patients (male, %) | Age, years mean ± SD (if provided) | H & Y stage | Intervention | Outcome |
|---|---|---|---|---|---|---|
| Parkinson Study Group19
(DATATOP) |
Stage I or II for fewer than 5 years | E: 399 (67) C: 401 (66) |
E: 61.1 ± 9.7 C: 61.1 ± 9.4 |
E: 1.6 ± 0.5 C: 1.7 ± 0.5 |
Selegiline 10 mg for 90 days | HAMD |
| Allain et al.20
(French Selegiline Multicenter Trial) |
No treatment, stage less than III | E: 48 (52.1) C: 45 (55.6) |
E: 64.5 ± 8.5 C: 65.4 ± 10.1 |
E: 1.8 ± 0.5 C: 1.7 ± 0.4 |
Selegiline 10 mg for 90 days | HAMD |
| Schapira et al.18
(Study 017) |
Stage I to III for fewer than 5 years | E1: 80 (67.5) E2: 69 (62.3) C: 78 (60.3) |
E1: 56.6 E2: 59.8 C: 57.0 |
E1: 1.9 ± 0.6 E2: 1.8 ± 0.6 C: 1.9 ± 0.7 |
Safinamide 100 (E1) or 200 (E2) mg for 18 months |
HAMD |
| Borgohain et al.15 | Middle-to-late-stage PD, experiencing motor fluctuations |
E1: 223 (70.4) E2: 224 (72.8) C: 222 (72.1) |
E1: 60.1 ± 9.65 E2: 60.1 ± 9.19 C: 59.4 ± 9.41 |
E1: 2.8 ± 0.6 E2: 2.8 ± 0.6 C: 2.8 ± 0.7 |
Safinamide 50 (E1) or 100 (E2) mg for 24 weeks | HAMD |
| Barone et al.16 | Stage ⩾1 and ⩽3; BDI-I ⩾15 | E: 58 (46.6) C: 65 (58.5) |
E: 66.0 ± 8.74 C: 66.1 ± 8.35 |
E: 1.8 ± 0.6 C: 1.9 ± 0.6 |
Rasagiline 1 mg for 12 weeks | BDI |
| Schapira [2017]17 | Disease duration >3 years, stages I–IV, off time >1.5 h/day | E: 274 (62.4) C: 275 (68.4) |
E: 61.7 ± 9.0 C: 62.1 ± 8.9 |
E: 2.5 ± 0.6 C: 2.5 ± 0.6 |
Safinamide 100 mg for 24 weeks | HAMD |
BDI, Beck Depression Inventory; C, control group; E, experimental group; HAMD, Hamilton Depression Rating Scale; H & Y, Hoehn and Yahr (Supplemental material Table S3); PD, Parkinson’s disease; SD, standard deviation.